Marinobufagenin Predicts and Resibufogenin Prevents Preeclampsia: A Review of the Evidence

Abstract

Objective The purpose of this review is to provide information detailing the existing evidence with regard to the hypothesis that marinobufagenin (MBG) is an important etiologic and predictive factor in preeclampsia (PE). In addition, evidence describing the role of the antagonist to MBG, resibufogenin (RBG), in the prevention and/or treatment of this disorder is provided.

Study Design The studies outlined were performed in an animal model of PE, in in vitro experiments, and in human studies.

Results Data have been obtained that strongly support the hypothesis that ~60 to 70% of PE patients demonstrate elevations in urinary and serum MBG levels. In the animal model, the entire syndrome can be prevented by the administration of RBG beginning early in pregnancy.

Conclusion Expanded human trials of MBG as a predictor of the later development of PE are warranted as are studies of the efficacy and safety of RBG as a preventative/therapy.

Keywords

preeclampsia - bufadienolides - marinobufagenin - resibufogenin

• References

• 1 Pridjian G, Puschett JB. Preeclampsia. Part 1: clinical and pathophysiologic considerations. Obstet Gynecol Surv 2002; 57: 598-618
• 2 Pridjian G, Puschett JB. Preeclampsia. Part 2: experimental and genetic considerations. Obstet Gynecol Surv 2002; 57: 619-640
• 3 Puschett JB, Agunanne E, Uddin MN. Marinobufagenin, resibufogenin and preeclampsia. Biochim Biophys Acta 2010; 1802: 1246-1253
• 4 Schoner W, Scheiner-Bobis G. Endogenous and exogenous cardiac glycosides: their roles in hypertension, salt metabolism, and cell growth. Am J Physiol Cell Physiol 2007; 293: C509-C536
• 5 Gonick HC, Ding Y, Vaziri ND, Bagrov AY, Fedorova OV. Simultaneous measurement of marinobufagenin, ouabain, and hypertension-associated protein in various disease states. Clin Exp Hypertens 1998; 20: 617-627
• 6 Averina IV, Tapilskaya NI, Reznik VA , et al. Endogenous Na/K-ATPase inhibitors in patients with preeclampsia. Cell Mol Biol (Noisy-le-grand) 2006; 52: 19-23
• 7 Lopatin DA, Ailamazian EK, Dmitrieva RI , et al. Circulating bufodienolide and cardenolide sodium pump inhibitors in preeclampsia. J Hypertens 1999; 17: 1179-1187
• 8 Tian J, Haller S, Periyasamy S , et al. Renal ischemia regulates marinobufagenin release in humans. Hypertension 2010; 56: 914-919
• 9 Bagrov AY, Fedorova OV, Dmitrieva RI , et al. Characterization of a urinary bufodienolide Na+ ,K+-ATPase inhibitor in patients after acute myocardial infarction. Hypertension 1998; 31: 1097-1103
• 10 Bagrov AY, Fedorova OV, Austin-Lane JL, Dmitrieva RI, Anderson DE. Endogenous marinobufagenin-like immunoreactive factor and Na+, K+ ATPase inhibition during voluntary hypoventilation. Hypertension 1995; 26: 781-788
• 11 Laragh JH. Vasoconstriction-volume analysis for understanding and treating hypertension: the use of renin and aldosterone profiles. Am J Med 1973; 55: 261-274
• 12 Uddin MN, McLean LB, Hunter FA , et al. Vascular leak in a rat model of preeclampsia. Am J Nephrol 2009; 30: 26-33
• 13 Roberts JM, Taylor RN, Musci TJ, Rodgers GM, Hubel CA, McLaughlin MK. Preeclampsia: an endothelial cell disorder. Am J Obstet Gynecol 1989; 161: 1200-1204
• 14 Roberts JM. Endothelial dysfunction in preeclampsia. Semin Reprod Endocrinol 1998; 16: 5-15
• 15 Puschett JB. The role of excessive volume expansion in the pathogenesis of preeclampsia. Med Hypotheses 2006; 67: 1125-1132
• 16 Morrison AC, Srinivas SK, Elovitz MA, Puschett JB. Genetic variation in solute carrier genes is associated with preeclampsia. Am J Obstet Gynecol 2010; 203: 491 , e1–e491, e13
• 17 Chesley LC. Sodium retention and pre-eclampsia. Am J Obstet Gynecol 1966; 95: 127-132
• 18 Ianosi-Irimie M, Vu HV, Whitbred JM , et al. A rat model of preeclampsia. Clin Exp Hypertens 2005; 27: 605-617
• 19 Vu HV, Ianosi-Irimie MR, Pridjian CA , et al. Involvement of marinobufagenin in a rat model of human preeclampsia. Am J Nephrol 2005; 25: 520-528
• 20 Agunanne E, Horvat D, Harrison R , et al. Marinobufagenin levels in preeclamptic patients: a preliminary report. Am J Perinatol 2011; 28: 509-514
• 21 Scott DE. Anemia in pregnancy. Obstet Gynecol Annu 1972; 1: 219-244
• 22 LaMarca HL, Morris CA, Pettit GR, Nagowa T, Puschett JB. Marinobufagenin impairs first trimester cytotrophoblast differentiation. Placenta 2006; 27: 984-988
• 23 Uddin MN, Horvat D, Glaser SS , et al. Marinobufagenin inhibits proliferation and migration of cytotrophoblast and CHO cells. Placenta 2008; 29: 266-273
• 24 Uddin MN, Horvat D, Glaser SS, Mitchell BM, Puschett JB. Examination of the cellular mechanisms by which marinobufagenin inhibits cytotrophoblast function. J Biol Chem 2008; 283: 17946-17953
• 25 Mitchell BM, Cook LG, Danchuk S, Puschett JB. Uncoupled endothelial nitric oxide synthase and oxidative stress in a rat model of pregnancy-induced hypertension. Am J Hypertens 2007; 20: 1297-1304
• 26 Danchuk S, Sukhanov S, Horvat D, Uddin MN, Puschett JB. Effects of resibufogenin in experimental hypertension. Am J Nephrol 2008; 28: 8-13
• 27 Horvat D, Severson J, Uddin MN, Mitchell B, Puschett JB. Resibufogenin prevents the manifestations of preeclampsia in an animal model of the syndrome. Hypertens Pregnancy 2010; 29: 1-9
• 28 Maynard SE, Min JY, Merchan J , et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003; 111: 649-658
• 29 Levine RJ, Maynard SE, Qian C , et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004; 350: 672-683
• 30 Wallukat G, Homuth V, Fischer T , et al. Patients with preeclampsia develop agonistic autoantibodies against the angiotensin AT1 receptor. J Clin Invest 1999; 103: 945-952
• 31 Uddin MN, Agunanne E, Horvat D, Puschett JB. Alterations in the renin-angiotensin system in a rat model of human preeclampsia. Am J Nephrol 2010; 31: 171-177
• 32 Agunanne EE, Uddin MN, Horvat D, Puschett JB. Contribution of angiogenic factors in a rat model of pre-eclampsia. Am J Nephrol 2010; 32: 332-339
• 33 Uddin MN, Horvat D, Childs EW, Puschett JB. Marinobufagenin causes endothelial cell monolayer hyperpermeability by altering apoptotic signaling. Am J Physiol Regul Integr Comp Physiol 2009; 296: R1726-R1734
• 34 Lee MR, Dominguez C. MAP kinase p38 inhibitors: clinical results and an intimate look at their interactions with p38alpha protein. Curr Med Chem 2005; 12: 2979-2994
• 35 Prakash J, Sandovici M, Saluja V , et al. Intracellular delivery of the p38 mitogen-activated protein kinase inhibitor SB202190 [4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)1H-imidazole] in renal tubular cells: a novel strategy to treat renal fibrosis. J Pharmacol Exp Ther 2006; 319: 8-19
• 36 Uddin MN, Horvat D, Glaser SS, Mitchell BM, Puschett JB. Examination of the cellular mechanisms by which marinobufagenin inhibits cytotrophoblast function. J Biol Chem 2008; 283: 17946-17953
• 37 Uddin MN, Horvat D, Demorrow S, Agunanne E, Puschett JB. Marinobufagenin is an upstream modulator of Gadd45a stress signaling in preeclampsia. Biochim Biophys Acta 2011; 1812: 49-58
• 38 Vu H, Ianosi-Irimie M, Danchuk S , et al. Resibufogenin corrects hypertension in a rat model of human preeclampsia. Exp Biol Med (Maywood) 2006; 231: 215-220
• 39 Roux PP, Blenis J. ERK and p38 MAPK-activated protein kinases: a family of protein kinases with diverse biological functions. Microbiol Mol Biol Rev 2004; 68: 320-344
• 40 Uddin MN, Agunanne EE, Horvat D, Puschett JB. Resibufogenin administration prevents oxidative stress in a rat model of human preeclampsia. Hypertens Pregnancy 2012; 31: 70-78